Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	382.64B
Revenue (ttm)	167.66B
Net Income (ttm)	-78.06B
Shares Out	12.42M
EPS (ttm)	-6,510.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,121
Average Volume	38,846
Open	32,000
Previous Close	32,000
Day's Range	30,300 - 32,000
52-Week Range	16,780 - 39,400
Beta	-0.23
RSI	67.61
Earnings Date	Aug 13, 2025

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2000
• Employees: 426
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.